9 – Calcitonin Treatment in Postmenopausal Osteoporosis
作者： Stuart L. Silverman
DOI: 10.1016/B978-012068705-3/50010-3
关键词: Placebo 、 Pregnancy 、 Nasal spray 、 Calcium 、 Calcitonin 、 Homeostasis 、 Endocrinology 、 Analgesic 、 Internal medicine 、 Osteoporosis 、 Medicine
摘要: Calcitonin is a safe treatment for established osteoporosis and currently available as an injectable preparation. Clinical trials with either or nasal spray forms of salmon calcitonin have demonstrated the efficacy in increasing lumbar spine bone mass decreasing vertebral fracture rates (nasal form) patients osteoporosis. The use has been limited by decreased compliance due to side effects method delivery. availability formulation relatively few compared placebo increased convenience use. Both demonstrate analgesic osteoporotic individuals. also prevents hypercalcemia following calcium rich meals protects stores during periods stress such pregnancy, lactation, low dietary intake. Despite these biological responses, does not significant role homeostasis plasma normal
elsevier.com
sci-hub.se 参考文章(37)
L. Flicker, J. L. Hopper, R. G. Larkins, M. Lichtenstein, G. Buirski, J. D. Wark, Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis Osteoporosis International. ,vol. 7, pp. 29- 35 ,(1997) , 10.1007/BF01623456
Rosario Foti, Umberto Martorana, Marco Broggini, Long-term tolerability of nasal spray formulation of salmon calcitonin Current Therapeutic Research-clinical and Experimental. ,vol. 56, pp. 429- 435 ,(1995) , 10.1016/0011-393X(95)85012-0
B. Ongphiphadhanakul, N. Piaseu, L. Chailurkit, R. Rajatanavin, Suppression of bone resorption in early postmenopausal women by intranasal salmon calcitonin in relation to dosage and basal bone turnover. Calcified Tissue International. ,vol. 62, pp. 379- 382 ,(1998) , 10.1007/S002239900448
H. Rico, M. Revilla, E. R. Hernández, L. F. Villa, M. Alvarez de Buergo, Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: A prospective study Calcified Tissue International. ,vol. 56, pp. 181- 185 ,(1995) , 10.1007/BF00298606
H.M. Frost, Personal experience in managing acute compression fractures, their aftermath, and the bone pain syndrome, in osteoporosis. Osteoporosis International. ,vol. 8, pp. 13- 15 ,(1998) , 10.1007/S001980050042
J. H. Healey, S. A. Paget, P. Williams-Russo, T. P. Szatrowski, R. Schneider, H. Spiera, H. Mitnick, K. Ales, P. Schwartzberg, A Randomized Controlled Trial of Salmon Calcitonin to Prevent Bone Loss in Corticosteroid-Treated Temporal Arteritis and Polymyalgia Rheumatica Calcified Tissue International. ,vol. 58, pp. 73- 80 ,(1996) , 10.1007/BF02529727
Donato Agnusdei, Mario Montagnani, Stefano Gonnelli, Roberto Civitelli, An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss Calcified Tissue International. ,vol. 50, pp. 381- 383 ,(1992) , 10.1007/BF00301638
S Takahashi, S Goldring, M Katz, S Hilsenbeck, R Williams, G D Roodman, Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. Journal of Clinical Investigation. ,vol. 95, pp. 167- 171 ,(1995) , 10.1172/JCI117634
K. Overgaard, M. A. Hansen, S. B. Jensen, C. Christiansen, Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ. ,vol. 305, pp. 556- 561 ,(1992) , 10.1136/BMJ.305.6853.556
J. M. Cardona, E. Pastor, Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials. Osteoporosis International. ,vol. 7, pp. 165- 174 ,(1997) , 10.1007/BF01622285